卓正医疗正式登陆港交所：开盘上涨超50%，「医疗界Costco」积极拥抱AI新时代

Core Viewpoint - The rapid development of artificial intelligence and biomedicine is leading to unprecedented changes in the healthcare service industry [2][6]. IPO Details - Zhuozheng Medical Holdings Limited is set to be listed on the Hong Kong Stock Exchange on February 6, 2026, under the stock code "2677" [2]. - The company issued a total of 4,750,000 shares, raising a total of HKD 284 million, with a subscription rate of 2730.73 times for the public offering and 5.79 times for the international offering [2]. - Notable cornerstone investors include He Xiaopeng, CEO of Xiaopeng Motors, who subscribed for USD 1 million, and other tech companies with AI attributes [3]. Market Position and Growth - Zhuozheng Medical ranks first and second among private high-end comprehensive medical service institutions in terms of the number of cities covered and the number of paid patient visits in 2024 [9]. - The company has a strong reputation based on service quality, with high net promoter scores (NPS) of 81.1, 86.4, 85.9, and 87.6 from 2022 to 2025 [9]. Membership and Customer Retention - As of August 31, 2025, Zhuozheng Medical had 116,542 member accounts, with renewal rates increasing from 42% in 2022 to 67% in 2025 [11]. - The patient return rate also improved from 75.7% in 2022 to 82.7% in 2025, indicating strong customer loyalty [11]. Business Model - Zhuozheng Medical adopts a Costco-like model in the healthcare sector, focusing on a membership system and high-value services to drive growth [11][13]. - The company offers a range of services that cater to high-frequency health needs, allowing for longer customer retention periods and higher consumption frequency [13]. Financial Performance - Zhuozheng Medical achieved revenue growth from CNY 473 million in 2022 to CNY 959 million in 2024, with a compound annual growth rate (CAGR) of 42.2% [14]. - The gross profit also increased significantly, from CNY 44 million in 2022 to CNY 226 million in 2024, with a CAGR of 126.7% [14]. - The company turned profitable in 2024, with an adjusted net profit of approximately CNY 10.45 million in the first eight months of 2025 [14]. Investor Support - Zhuozheng Medical has received investments from notable firms such as Tencent, Matrix Partners, Tiantu Capital, and others, indicating strong institutional support [16][17]. - Investors believe that the company is well-positioned to meet the growing demand for high-quality healthcare services in China [17][18].